Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

BOSTON —Small interfering RNA technology has the potential to become a novel treatment approach in cardiovascular medicine, according to Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA. In this ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

Small interfering RNA (siRNA) is a class of double-stranded RNA molecules, typically 20-25 base pairs in length, that play a crucial role in the RNA interference (RNAi) pathway. siRNAs are involved in ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...